PHAR News and Press, Pharming Group N.V. From 07/01/21

Orchard Therapeutics (ORTX) and Pharming Group (PHAR) announce a strategic collaboration to research, develop, manufacture and commercialize OTL-105, an investigational ex vivo autologous hematopoietic stem cell ((HSC)) gene therapy for the treatment of hereditary angioedema ((HAE)), a rare d...

Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant clinical expertise and global commercialization infrastructure ...